EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Nicholas Brian Shannon iD, Bruce Ashford iD

Head & Neck · 2026-09 · 48 (9) · 2570-2583

DOI: 10.1002/hed.70368 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Head & Neck, online erschienen am 22.06.2026. Verfasst von Nicholas Brian Shannon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Illawarra Shoalhaven Local Health District, Wollongong Hospital, Wollongong, New South Wales, Australia. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients experiencing recurrence. The integration of immune checkpoint inhibitors (ICIs) into the neoadjuvant window represents a paradigm shift toward biologically adapted surgical intervention.

Results

Neoadjuvant immunotherapy capitalizes on an intact immune substrate to create an in situ vaccine, avoiding the post‐surgical immune desert that limits adjuvant efficacy. Emerging phase III data confirm that perioperative ICI significantly improves event‐free survival. Successful implementation requires the surgeon to navigate unique diagnostic challenges, such as distinguishing rare but anatomically risky pseudoprogression from true progression. While combination therapies (chemoimmunotherapy or immunoradiotherapy) yield higher pathologic complete response rates, they also increase toxicity. Intraoperatively, ICI monotherapy generally preserves tissue planes without increasing surgical delays or major wound complications. Standard biomarkers like PD‐L1 and TMB, alongside emerging tools such as liquid biopsy (ctDNA), are essential for patient selection and dynamic monitoring.

Conclusions

The transition to neoadjuvant immunotherapy facilitates future surgical de‐escalation and function‐preserving approaches. To optimize outcomes, the modern surgeon must act as a surgical immunologist, interpreting translational data to guide real‐time operative planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsImmunotherapyImmune Checkpoint InhibitorsSquamous Cell Carcinoma of Head and NeckHumansNeoadjuvant TherapyPerioperative Care

Stichwörter der Autor:innen

head and neck squamous cell carcinomaimmunotherapyneoadjuvant therapyperioperativesurgical de‐escalation

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Illawarra Shoalhaven Local Health District, Wollongong Hospital, Wollongong, New South Wales, Australia.
  • Department of Head and Neck Surgery, National Cancer Centre Singapore, Singapore, Singapore.
  • Department of Head and Neck Surgery, Singapore General Hospital, Singapore, Singapore.
  • Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.

ORCID-Profile: Nicholas Brian Shannon, Bruce Ashford

Zitieren

APA

Shannon, N. B., & Ashford, B. (2026). Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review. Head & Neck, 48(9), 2570-2583. https://doi.org/10.1002/hed.70368

Vancouver

Shannon NB, Ashford B. Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review. Head & Neck. 2026;48(9):2570-2583. doi:10.1002/hed.70368

BibTeX
@article{Shannon2026,
  author = {Shannon, Nicholas Brian and Ashford, Bruce},
  title = {Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review},
  journal = {Head & Neck},
  year = {2026},
  volume = {48},
  number = {9},
  pages = {2570--2583},
  doi = {10.1002/hed.70368}
}
Kostenlos starten →